James P. Moran
Known title: DirectorCIK: 0001907094
James P. Moran's purchase track record
James P. Moran has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/25/2024 | IGC | $200K | +8.8% | -8.8% | -0.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IGC | ▲ Buy | Option Exercise | 80,000 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 50,000 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Open Market | 588,235 | $200K | 9/25/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 50,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 33,334 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 80,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 28,500 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 29,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 50,000 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 33,334 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Grant | 50,000 | $0 | 1/18/2022 | View on chart |
| IGC | ▲ Buy | Grant | 100,000 | $0 | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.